<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01497002</url>
  </required_header>
  <id_info>
    <org_study_id>OSHO#069</org_study_id>
    <nct_id>NCT01497002</nct_id>
  </id_info>
  <brief_title>Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML&gt;60a</brief_title>
  <acronym>AML2004</acronym>
  <official_title>Randomized Phase III Study Comparing the OSHO Arm to the Standard Intergroup Arm.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Improvement of the treatment-results in elderly patients with acute myeloid leukemia through
      intensification of consolidation chemotherapy and/or allografting as consolidative
      immunotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Measuring EFS depending on induction therapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2005</start_date>
  <completion_date type="Actual">July 18, 2018</completion_date>
  <primary_completion_date type="Actual">July 18, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>after 5 years</time_frame>
    <description>comparison of event free survival (OSHO arm versus Standard intergroup arm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>at 5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LFS</measure>
    <time_frame>at 5 years</time_frame>
    <description>leukemia free survival</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1222</enrollment>
  <condition>Acute Myeloid Leukaemia</condition>
  <arm_group>
    <arm_group_label>standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OSHO - intensified consolidation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intermediate dose AraC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OSHO - allografting as consolidation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>allogeneic stem cell Transplantation versus no transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.</description>
    <arm_group_label>OSHO - intensified consolidation</arm_group_label>
    <arm_group_label>standard arm</arm_group_label>
    <other_name>AraC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human stem cells</intervention_name>
    <description>Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate</description>
    <arm_group_label>OSHO - allografting as consolidation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes with age &gt; 60 years and newly diagnosed acute myeloid leukaemia
             as defined by new WHO classification

          -  written informed consent

        Exclusion Criteria:

          -  pretreatment of leukemia

          -  no informed consent

          -  simultaneous inclusion in other studies

          -  mental disability

          -  contraindication for intensive chemotherapy

          -  AML FAB M3

          -  contraindication for allogeneic stem cell transplantation

          -  restriction of following organ functions:

          -  creatinine-clearance &lt; 50 ml/min

          -  cardiac ejection fraction &lt; 40 %

          -  severe pulmonary restriction

          -  bilirubin &gt; 2x ULN; SGOT and SGPT &gt; 4x ULN

          -  uncontrolled hypertension

          -  severe uncontrolled metabolism disturbance

          -  Karnofsky-performance-score &lt; 70%

          -  hepatitis C

          -  other malignancy

          -  age of unrelated donor &gt;70 years and age of related donor &gt;75 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dietger Niederwieser, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Leipzig, Hematology</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-leukaemie.de/trial/detail_en.html?id=231</url>
    <description>AML 2004 OSHO #069 (Elderly)</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 21, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2011</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Sandra Otto</investigator_full_name>
    <investigator_title>Prof. Dietger Niederwieser</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

